ArticleBreast cancer research : BCR2021

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer.

Kamila Kaminska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.